From Target to Leads in 0 Weeks
Generate millions of drug-like molecules with optimized pharmacophores tailored to your target's binding pocket. Our Janak RL-GAN employs reinforcement learning to explore unexplored chemical space beyond existing compound libraries.
Validated approach: Successfully identified lead compounds for CDK9, BRD4, and EGFR targets with experimental hit rates exceeding 70%. All generated molecules pass Lipinski's Rule of Five, synthetic accessibility scores, and comprehensive PAINS filtering.
What You Get
Complete hit discovery package ready for experimental validation
10M+ De Novo Structures
Target-specific chemical scaffolds with optimized pharmacophores
Top 100 Lead Compounds
Structure-activity optimized, ADMET-filtered, synthetically accessible
Complete SAR Package
Binding poses, interaction profiles, synthetic routes, ADMET predictions
Simple. Fast. Powerful.
From target to validated hits in 4 weeks
Target Profiling
Analyze binding pocket, identify key interactions, define pharmacophore
De Novo Design
Generate 10M+ drug-like scaffolds optimized for target
In Silico Screening
ADMET profiling, docking, PAINS filtering, QED scoring
Lead Delivery
Top 100 compounds with IC₅₀ predictions, synthetic routes
Powered by Janak RL-GAN
Our proprietary AI doesn't just search existing molecules — it creates entirely new chemical matter optimized for your specific target
CDK9 Kinase Inhibitor Campaign
Ready to Accelerate Your Discovery?
Share your target. Get novel hits in 4 weeks. It's that simple.